Description of Statera Biopharma Inc Fka Cytocom Inc's Business Segments
Statera Biopharma Inc. formerly known as Cytocom Inc. focuses on the development and commercialization of innovative therapeutics that harness the body’s immune system to treat various diseases. The company aims to provide solutions primarily in the areas of immune-mediated disorders and other serious health conditions. Here’s an extensive overview of its segments, products, and services:
Segments
1. Pharmaceutical Development: Statera Biopharma is heavily involved in research and development (R&D) to create novel therapeutics. This segment focuses on leveraging cellular and molecular biology to develop drugs that modulate the immune response.
2. Immunotherapy: The companys immunotherapy segment targets various immune disorders and diseases, focusing on the concept of restoring immune balance rather than simply suppressing the immune system.
3. Licensing and Partnerships: Statera Biopharma actively seeks strategic partnerships with other biotech firms and pharmaceutical companies to co-develop or license its proprietary technologies and drugs.
Products
1. Lead Therapeutics: - STAT-201: This product is designed for the treatment of auto-inflammatory diseases and conditions where the immune system is dysregulated. It aims to enhance the body’s natural immune response, helping to reduce inflammation and restore normal immune function. - STAT-202: Targeted for cancer therapy, STAT-202 is developed to trigger specific immune responses against tumor cells, thereby potentially improving outcomes in oncology patients. - Other Investigational Products: Statera is also engaged in the development of various other investigational drugs aimed at various autoimmune diseases, infections, and cancer. Each product typically undergoes rigorous clinical trials to assess efficacy and safety before regulatory approval.
2. Biological Products: - Statera Biopharma offers biological products that include monoclonal antibodies, proteins, and peptides, targeting various biological pathways involved in disease processes. These products often serve as both therapeutic agents and research tools.
3. Combination Therapies: The company also explores combination therapies, where its products may be used alongside existing treatments to improve efficacy, reduce side effects, or target multiple pathways in diseases.
Services
1. Clinical Trial Services: Statera provides clinical trial design, management, and execution services. This includes Phase I, II, and III clinical studies to evaluate the safety, tolerability, and efficacy of its therapeutics.
2. Regulatory Affairs Support: The company offers expertise in navigating the complex regulatory landscape required for drug approval, including preparing and submitting Investigational New Drug (IND) applications and collaborating with regulatory agencies.
3. Consultation and Advisory Services: Statera collaborates with healthcare professionals and organizations to provide consultation on drug development processes, regulatory compliance, and clinical strategy.
4. Partnerships for Research and Development: By partnering with academic institutions, research hospitals, and other biopharmaceutical companies, Statera facilitates joint research initiatives aimed at discovering new therapeutic approaches and understanding disease mechanisms.
Statera Biopharma Inc. is committed to advancing medical science through innovative therapies and solutions that address unmet medical needs, especially those related to immune system dysfunction. The companys business model incorporates extensive R&D efforts, collaboration with industry partners, and a focus on developing therapies that work with the bodys natural immune mechanisms.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
